To the Editor: Nosocomial infections caused by Pseudomonas aeruginosa often prove difficult to treat because of their resistance to multiple drugs. Carbapenems play a pivotal role in the management of severe multidrug-resistant gram-negative Enterobacteriaceae and P. aeruginosa infections. However, reports in Australia of carbapenem resistance due to production of a variety of carbapenemases, including metallo-β-lactamases (MBLs), have been increasing alarmingly.1,2 We wish to report the first clinical case of a VIM-1-producing MBL in Sydney. To our knowledge, this is the first reported locally acquired case of a P. aeruginosa strain producing acquired VIM-1 MBL in Australia.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 Department of Microbiology and Infectious Diseases, Concord Hospital, Sydney, NSW.
- 2 Institute for the Biotechnology of Infectious Diseases, Faculty of Science, University of Technology Sydney, Sydney, NSW.
- 1. Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of the metallo-β-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41: 1549-1556.
- 2. Espedido BA, Thomas LC, Iredell JR. Metallo-β-lactamase or extended-spectrum β-lactamase: a wolf in sheep’s clothing. J Clin Microbiol 2007; 45: 2034-2036.
- 3. Mesaros N, Nordmann P, Plésiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007; 13: 560-578.
- 4. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-325.